Rapamycin in ME/CFS: Promise, Proof, and the Path Forward

An Evidence-Based Clinical Review

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

October 9, 2026

About Dr. Kim

Yoon Hang Kim, MD, MPH is a board-certified physician with over 20 years of clinical experience spanning integrative medicine, functional medicine, medical acupuncture, and preventive medicine. A University of Arizona/Andrew Weil Center for Integrative Medicine fellowship-trained physician, Dr. Kim holds certifications in preventive medicine, medical acupuncture, and integrative & functional medicine. He specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 8 books including MCAS: Epidemic in Plain Sight and LDN Primer, and has published more than 25 peer-reviewed articles. He is the founder of the LDN Support Group.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com

Introduction

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is one of medicine’s most vexing unsolved problems — a serious, biologically grounded illness affecting an estimated 836,000–3.3 million Americans (CDC), for which no FDA-approved disease-modifying treatment exists. Clients are frequently dismissed, misdiagnosed for years, and left with management strategies that address symptoms rather than underlying mechanisms. Into that vacuum, a growing body of clinician-researchers has begun asking whether rapamycin — a drug already in clinical use for transplant immunosuppression, certain cancers, and rare genetic syndromes — might hold therapeutic relevance for ME/CFS through its effects on the mTOR/autophagy axis.

This piece examines what the published evidence actually shows: two open-label observational cohorts with promising but uncontrolled findings, a coherent biological hypothesis linking mTOR dysregulation to ME/CFS pathophysiology, and a planned randomized placebo-controlled trial that will be the genuine evidentiary test. The goal is neither to dismiss the signal nor to overstate it — but to read the data honestly and communicate what practicing clinicians need to know.

Background: ME/CFS and the Treatment Desert

ME/CFS is defined by profound fatigue lasting six months or longer, post-exertional malaise (PEM) — the hallmark worsening of symptoms following physical or cognitive effort — cognitive impairment, unrefreshing sleep, and, in many clients, orthostatic intolerance. The 2015 Institute of Medicine report reframed the illness as a serious, complex, systemic disease requiring urgent research investment. Despite that call, disease-modifying treatments remain entirely absent from the approved pharmacopoeia.

The biology of ME/CFS is heterogeneous and incompletely understood. Proposed mechanisms include immune dysregulation, autonomic nervous system dysfunction, mitochondrial energy metabolism abnormalities, impaired cellular stress responses, and persistent post-infectious immune activation — particularly relevant given the substantial overlap between ME/CFS and Long COVID.

In this context, the rapamycin program is notable not merely because it reports clinical improvement, but because it offers a mechanistically specific hypothesis — one grounded in well-characterized cellular biology — and has produced peer-reviewed, albeit uncontrolled, data to test it.

The Mechanistic Hypothesis: mTOR, Autophagy, and ATG13

Rapamycin (sirolimus) is a macrolide compound that inhibits mTOR complex 1 (mTORC1), a nutrient- and energy-sensing kinase that serves as a master regulator of cellular growth, protein synthesis, immune activation, and — critically — autophagy. Autophagy is the cell’s housekeeping mechanism for degrading and recycling damaged proteins and dysfunctional organelles. When mTOR is constitutively active, autophagy is suppressed; when mTOR is inhibited, autophagic activity may be promoted.

The investigative group behind this program proposes that a biologically distinct subgroup of ME/CFS is characterized by persistent mTOR overactivation and impaired autophagy mediated through an ATG13-dependent pathway. In this model, increased mTORC1-dependent phosphorylation of ATG13 at serine 258 (pSer258-ATG13) suppresses ULK1 complex activity and autophagy initiation — not by preventing complex assembly, which remains constitutive in mammalian cells, but by inhibiting the complex’s kinase function (Puente et al., 2016). The downstream consequence is impaired autophagic clearance of damaged cellular material, contributing to immune activation, oxidative stress, mitochondrial dysfunction, and the energy deficit that may underlie PEM and fatigue.

mTOR overactivation → impaired ATG13-mediated autophagy → cellular stress and energy dysfunction → ME/CFS symptom expression

Low-dose rapamycin → mTORC1 inhibition → promoted autophagic activity → potential symptom improvement

This is a biologically coherent framework. What it is not, yet, is a validated ME/CFS disease model. The biomarkers in question (pSer258-ATG13, BECLIN-1) are investigational; changes in these circulating proteins cannot by themselves establish restoration of functional autophagic activity at the cellular level. Whether this mechanism drives ME/CFS pathophysiology in a defined subgroup — or represents an epiphenomenon — cannot be determined from uncontrolled observational data.

Phase I: The First Signal (2025)

The published Phase I pilot — reported in the Journal of Translational Medicine in 2025 by Ruan and colleagues — enrolled 86 adults with ME/CFS in a decentralized, uncontrolled, open-label study. Participants received generic oral sirolimus 6 mg once weekly for 90 days.

What was measured:  The study used four validated instruments — the Bell Activity Scale, the Specific Symptom Severity Scale, the Multidimensional Fatigue Inventory, and the SF-36. Blood biomarkers included pSer258-ATG13 and BECLIN-1 to assess autophagy-pathway signaling.

What was found:  Of 86 treated participants, 70 reached at least the first follow-up, and 40 completed the full 90-day protocol. The investigators classified 52 of the 70 (74.3%) as full or partial responders — however, this aggregate figure incorporated exploratory machine-learning-based classifications for the 30 participants who did not complete 90-day assessments. Among the 40 completers, 10 met full responder criteria, 24 were partial responders, and 6 were nonresponders. These findings should not be interpreted as a 74.3% observed clinical recovery rate. pSer258-ATG13 decreased and BECLIN-1 increased — directionally consistent with changes in autophagy-associated signaling proteins, though these peripheral measures cannot establish restoration of functional autophagic activity. No serious adverse events were reported.

What this supports:  Feasibility of a weekly 6 mg sirolimus regimen in ME/CFS over 90 days, a clinical signal worth testing in a controlled trial, mechanistic plausibility, and candidate endpoints and responder hypotheses for future studies.

What it cannot establish:  Efficacy. Without a concurrent placebo group, the observed improvement is inseparable from regression to the mean, expectation effects, natural symptom fluctuation, and attentional effects of trial participation. The responder classifications include model-based estimates for participants without complete data.

Phase II: Replication, Depth, and Honest Limitations (2026)

A 2026 Journal of Translational Medicine publication from the same research program reported a Phase II observational cohort using a compounded rapamycin formulation with sex-specific dose escalation. Of 108 consented, 78 began treatment; 65 (83.3% of those treated) completed the 90-day protocol.

Protocol:  Women began at 2.5 mg/week escalating toward 15 mg/week; men at 5 mg/week toward 20 mg/week. The investigators note this compounded preparation has substantially lower bioavailability than generic sirolimus — they estimate 15–18 mg/week compounded as roughly comparable to 5–6 mg/week generic. This equivalence is an investigator-reported assertion; the dosing schedules are not clinically interchangeable without independent verification.

What Phase II added:  The clinical signal extended to a second distinct cohort investigated by the same research group, using a different formulation. Mechanistic investigation deepened to include purine metabolism, mitochondrial oxidative phosphorylation, and microglial inflammatory signaling assays. This represents within-program replication, not independent external replication.

Limitations the authors name:  The absence of a placebo group, and molecular analyses weighted toward treatment responders. If biomarker analyses preferentially emphasized participants who improved, the apparent biological coherence of the proposed mechanism may be stronger in the data than in the full treated population. The authors deserve credit for naming this clearly.

What These Results Mean — and What They Cannot Establish

Why the signal is meaningful:  Convergence across multiple validated instruments (PEM, fatigue, orthostatic symptoms, function, quality of life) is more persuasive than a single exploratory lab change. The signal held across two distinct cohorts by the same group using different formulations — reducing the likelihood of a study-specific artifact, though not constituting independent replication. Autophagy-marker changes add biological coherence. Early tolerability data support advancing to a controlled trial.

Why it cannot answer the efficacy question:  The fundamental problem is causal inference. Neither study can estimate how participants would have fared without rapamycin. The observed improvement is a composite of: the drug’s true biological effect, placebo and contextual effects, natural symptom fluctuation (ME/CFS commonly waxes and wanes), regression to the mean, co-interventions, and expectation-related reporting changes.

An honest summary: these studies establish a signal worth testing rigorously, not a proven treatment effect.

The Missing Piece: What a Controlled Trial Would Tell Us

Simmaron Research has described plans for a 40-participant randomized, double-blind, placebo-controlled study, with a delayed-start rapamycin arm. The organization projects results around mid-2027, contingent on funding. The final protocol, enrollment status, and timeline require independent confirmation; the ClinicalTrials.gov registration (NCT06257420, first posted February 14, 2024) describes the observational component, not the randomized controlled trial. This planned study is the genuine evidentiary inflection point.

A well-designed RCT would:

Isolate the drug effect.  Random allocation balances baseline factors on average — though chance imbalances remain possible in a 40-person trial.

Estimate improvement under a control condition.  A placebo arm captures natural disease course, attention, hope, and contextual effects — necessary to determine whether rapamycin meaningfully exceeds that baseline.

Control for natural history.  ME/CFS fluctuates; clients often enroll during a worse period.

Enable pre-specified hypothesis testing.  Protecting against multiple-comparison and outcome-selection problems.

Validate or refute the biomarker hypothesis.  If autophagy-marker changes mediate the benefit under blinding, the mTOR hypothesis gains credibility. If the benefit disappears, the mechanism requires reassessment.

Clinical Considerations for Integrative Practitioners

Oral sirolimus is FDA-approved for prophylaxis of kidney transplant rejection and treatment of lymphangioleiomyomatosis (LAM). Separate formulations hold approvals for malignant PEComa and facial angiofibromas in tuberous sclerosis complex — these are not interchangeable. Its use in ME/CFS is entirely off-label and experimental.

Adverse effects:  Even at lower intermittent doses: aphthous stomatitis, dyslipidemia, cytopenias, edema, acneiform rash, diarrhea, proteinuria, delayed wound healing, and increased infection susceptibility. Noninfectious pneumonitis is an uncommon but potentially serious toxicity recognized in the prescribing information. Reproductive counseling is essential — sirolimus can cause fetal harm; women of childbearing potential require contraceptive counseling. The 90-day studies cannot reliably exclude uncommon or delayed adverse events.

Drug interactions:  Rapamycin is a CYP3A4 and P-glycoprotein substrate. Significant interactions with macrolide antibiotics, azole antifungals, calcium channel blockers, rifampin, anticonvulsants, and grapefruit products. Cannabidiol (CBD) and St. John’s wort — both commonly used in the ME/CFS population — are listed in current prescribing information and warrant explicit discussion.

Monitoring:  Periodic CBC, CMP, lipids, glycemic measures, hs-CRP, pregnancy testing. Pre-prescribing assessment of immunologic context and co-medications.

Communicating uncertainty:  A responsible conversation acknowledges the clinical interest of early data, is explicit that controlled proof does not yet exist, and ensures any off-label decision is genuinely informed — not driven by premature enthusiasm on either side of the clinical encounter.

Bottom Line

Two peer-reviewed, open-label observational cohorts from the same research program have reported that low-dose rapamycin is associated with meaningful improvement in client-reported fatigue, PEM, function, and quality of life in ME/CFS over 90 days — alongside exploratory biomarker changes consistent with the investigators’ proposed mTOR hypothesis. These findings are hypothesis-generating, mechanistically coherent, and sufficient to justify the next evidentiary step.

They are not proof of efficacy. The planned RAPA STEP 4 ME & COVID trial — projected mid-2027 — will be the meaningful test of whether rapamycin’s apparent benefit is real, durable, and attributable to the drug.

For clinical practice now: investigational interest, yes; off-label use, only with explicit uncertainty counseling, thorough drug-interaction review (including CBD and St. John’s wort), reproductive safety counseling, structured monitoring, and honesty about where the evidence stands.

References

1.  Ruan BT, et al. Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study. J Transl Med. 2025;23(1):1148. PMID: 41121328.

2.  Gile B, et al. Association of rapamycin treatment with modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: Phase-II observational study. J Transl Med. 2026;24:921. PMID: 42432754.

3.  ClinicalTrials.gov. NCT06257420. First posted Feb 14, 2024 (study start Dec 11, 2023). [Observational — not the planned RCT.]

4.  Institute of Medicine. Beyond ME/CFS: Redefining an Illness. National Academies Press; 2015.

5.  FDA. Step 3: Clinical Research. FDA Drug Development Process.

6.  Simmaron Research. Rapamycin Trial — RAPA STEP 4 ME & COVID. [Timeline subject to independent confirmation.]

7.  Puente C, et al. Nutrient-regulated phosphorylation of ATG13 inhibits starvation-induced autophagy. J Biol Chem. 2016;291(11):6026–6035. PMID: 26774122.

8.  Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th ed). Autophagy. 2021;17(1):1–382.

9.  U.S. NLM. Sirolimus tablets: prescribing information, revised July 2026. DailyMed.

10.  CDC. Clinical Overview of ME/CFS.

Yoon Hang Kim, MD, MPH is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com